Home | Welcome to Contract Pharma   
Last Updated Tuesday, October 21 2014
Print

Financial Report: Bristol-Myers Squibb



Published July 24, 2014
Bristol-Myers Squibb

2Q Revenues: $3.9 billion (-4%)

2Q Earnings: $334.0 million (-37%)

YTD Revenues: $7.7 billion (-2%)

YTD Earnings: $1.3 billion (+10%)

Comments: U.S. revenues decreased 7% to $1.9 billion in the quarter and International revenues were down 1% to $2.0 billion. Reyataz sales were down 16% to $362 million. The Sustiva Franchise was down 12% to $361 million. Eliquis sales grew by $159 million, Yervoy sales were up 38% to $321 million, Sprycel sales grew 18% to $368 million, and Orencia sales were $402 million, up 14%. R&D expenses were up 49% to $1.4 billion in the quarter and included impairment and acquisition-related charges of $458 million. Results in the quarter were impacted by the divestiture of the diabetes alliance.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On